A program that allows medical device sponsors to pursue FDA approval and Medicare coverage simultaneously is being “fully implemented and extended indefinitely” after a five-year pilot period, FDA announced in an Oct. 24 Federal Register notice. The notice states that CMS and FDA are actively looking for innovative products that might be eligible for the parallel review program, which is designed to reduce the time between when FDA grants PMA approval or a de novo classification and when Medicare issues a national coverage determination. This, the agencies hope, will improve outcomes by allowing patients to access new technologies more quickly.
FDA and CMS announced plans for the parallel review pilot program on Sept. 17, 2010. The agencies began recruiting companies for a pilot program on Oct. 11, 2011, and announced a two-year pilot program extension on Dec. 18, 2013
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?